title: Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer.
abstract: OBJECTIVE
  Anthracycline and taxanes are effective agents in advanced breast cancer and prolong survival times. Some patients achieve prolongation of life with capecitabine, gemcitabine, or vinorelbine, even after failure of both anthracycline and taxanes. We analyzed the efficacy and toxicity of gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer.
  
  
  METHODS
  The medical records of anthracycline- and taxane-pretreated metastatic breast cancer patients who received gemcitabine and vinorelbine combination chemotherapy at the Seoul National University Hospital were reviewed. Gemcitabine (1,000 mg/m(2)) and vinorelbine (25 mg/m(2)) were administered intravenously on days 1 and 8 every 3 weeks.
  
  
  RESULTS
  Between 2000 and 2006, 57 patients were eligible (median age, 45 years), and the median number of previous chemotherapy regimens was 3 (range, 1 approximately 5). The overall response rate was 30% (95% CI, 18.1 approximately 41.9), and the disease control rate was 46% (PR, 30%; SD, 16%). The median duration of follow-up was 33.4 months, the median time-to-progression (TTP) was 3.9 months, and the median overall survival was 10.8 months. None of the patients with patients with anthracycline and taxane primary resistance showed a response and the median TTP for these patients was significantly shorter than that of other patients (1.9 vs. 4.4 months; p=0.018). Although the efficacy was unsatisfactory in patients with both anthracycline and taxane primary resistance, gemcitabine and vinorelbine combination chemotherapy showed comparable efficacy in anthracycline- and/or taxane-sensitive patients and the patients with secondary resistance, even after failure of second-line therapy. Grade 3/4 hematologic toxicities included neutropenia (18.1%) and febrile neutropenia (0.3%), and non-hematologic toxicities were tolerable.
  
  
  CONCLUSIONS
  Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer was effective and tolerable.
authors.affiliation: Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
authors.forename: Hye Jin
authors.initials: HJ
authors.lastname: Kim
authors.forename: Jin-Soo
authors.initials: JS
authors.lastname: Kim
authors.forename: Myung-Deok
authors.initials: MD
authors.lastname: Seo
authors.forename: So-Yeon
authors.initials: SY
authors.lastname: Oh
authors.forename: Do-Youn
authors.initials: DY
authors.lastname: Oh
authors.forename: Jee Hyun
authors.initials: JH
authors.lastname: Kim
authors.forename: Se-Hoon
authors.initials: SH
authors.lastname: Lee
authors.forename: Dong-Wan
authors.initials: DW
authors.lastname: Kim
authors.forename: Seock-Ah
authors.initials: SA
authors.lastname: Im
authors.forename: Tae-You
authors.initials: TY
authors.lastname: Kim
authors.forename: Dae Seog
authors.initials: DS
authors.lastname: Heo
authors.forename: Yung-Jue
authors.initials: YJ
authors.lastname: Bang
references.citation: Oncology. 2003;64(4):479-80
references.pmid: 12759551
references.citation: J Clin Oncol. 2004 May 1;22(9):1621-9
references.pmid: 15117984
references.citation: Cancer Invest. 1990;8(2):313
references.pmid: 2400957
references.citation: Cancer Chemother Pharmacol. 2001 Aug;48(2):151-9
references.pmid: 11561781
references.citation: J Clin Oncol. 1995 Nov;13(11):2722-30
references.pmid: 7595730
references.citation: Breast Cancer Res Treat. 2001 Dec;70(3):163-9
references.pmid: 11804180
references.citation: Semin Oncol. 1989 Apr;16(2 Suppl 4):5-8
references.pmid: 2652320
references.citation: J Clin Oncol. 2004 Mar 15;22(6):1071-7
references.pmid: 15020608
references.citation: J Clin Oncol. 1995 Dec;13(12):2886-94
references.pmid: 8523051
references.citation: J Clin Oncol. 1995 Dec;13(12):2879-85
references.pmid: 8523050
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Semin Oncol. 1989 Apr;16(2 Suppl 4):2-4
references.pmid: 2540531
references.citation: J Clin Oncol. 2000 Jul;18(14):2733-9
references.pmid: 10894873
references.citation: Clin Breast Cancer. 2004 Jun;5(2):142-7
references.pmid: 15245619
references.citation: Br J Cancer. 2000 Feb;82(3):529-34
references.pmid: 10682660
references.citation: Ann Oncol. 2007 Jul;18(7):1152-8
references.pmid: 17264064
references.citation: Semin Radiat Oncol. 2003 Jul;13(3):176-81
references.pmid: 12903007
references.citation: Ann Oncol. 2000 Jul;11(7):873-5
references.pmid: 10997817
references.citation: J Clin Oncol. 1995 Nov;13(11):2731-6
references.pmid: 7595731
references.citation: Semin Oncol. 1996 Oct;23(5 Suppl 10):3-15
references.pmid: 8893876
references.citation: Cancer Chemother Pharmacol. 2003 Aug;52(2):147-52
references.pmid: 12764672
references.citation: Ann Oncol. 2005;16 Suppl 1:i10-2
references.pmid: 15888735
references.citation: Arch Surg. 2004 Jan;139(1):27-30; discussion 31
references.pmid: 14718270